tradingkey.logo
tradingkey.logo
Search

Eli Lilly and Co

LLY
Add to Watchlist
1164.410USD
+11.480+1.00%
Close 09-18 16:00ET
1.10TMarket Cap
41.30P/E TTM
After-hours 18:30 (ET)1164.890USD-0.110-0.01%
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+1.00%

5 Days

+4.37%

1 Month

-6.43%

6 Months

+28.83%

Year to Date

+8.87%

1 Year

+55.82%

Key Figures

1144.495Open
1170.750High
606.96KVolume
41.30P/E TTM
25.98P/E Dynamic
6.230Dividend TTM
0.06%Turnover Ratio
1152.930Prev. Close
1134.410Low
703.98MTurnover
103.55P/E Static
32.37P/B
0.54%Div Yield TTM
24.54%ROA
1292.65052wk High
99.10Volume Ratio
10.59BNet Profit
941.50MShares
28.2003EPS TTM
0.53Beta
107.65%ROE
707.58752wk Low
3.15%Amplitude
85.78%Gross Margin
1.10TMarket Cap
1.64Reward/Risk
2.26%Risk Rate
Recent
Earnings
Moderna Inc Stock (MRNA) Moved Up by 14.21% on Sep 21: Drivers Behind the Movement

• Moderna stock rose due to positive Phase 3 oncology trial results and upcoming congress presentations. • FDA approval of updated COVID-19 vaccines and capital-raising initiatives reinforced institutional financial confidence. • Moderna reported annual revenue of $1.94 billion and a net loss of $2.82 billion.

TradingKey4 hours ago
Novo Nordisk A/S Stock (NVO) Moved Down by 7.86% on Sep 21: A Full Analysis

• Novo Nordisk faced downward pressure after its Capital Markets Day strategic update. • Eli Lilly competition and patent expirations raised concerns over market dominance. • The MACD value of negative 0.874 indicates a sell signal.

TradingKey8 hours ago
Moderna Inc Stock (MRNA) Moved Up by 7.25% on Sep 17: Facts Behind the Movement

• Macroeconomic tailwinds and risk-on sentiment drove Moderna's strong upward rally and volatility. • Positive late-stage clinical data for intismeran expanded valuation expectations for oncology. • Analyst upgrades and institutional demand absorbed selling pressure from routine insider sales.

TradingKeyThu, Sep 17
Novo Nordisk A/S Stock (NVO) Moved Up by 3.02% on Sep 17: What Signal Does It Send?

• Novo Nordisk partnered with Orbis Medicine for AI-driven oral cardiometabolic drug discovery. • European regulators issued a favorable marketing recommendation for Frehemgo in hemophilia A. • The company reported $46.70B in annual revenue and $15.48B in net profit.

TradingKeyThu, Sep 17
Tempus AI Inc Stock (TEM) Moved Up by 7.35% on Sep 15: What Investors Need To Know

• Tempus AI experienced strong buying momentum and pronounced intraday price volatility. • CEO Eric Lefkofsky presented a compelling revenue growth outlook at conference. • The company reported an annual revenue of $1.27B and net profit of $-245.03M.

TradingKeyTue, Sep 15
Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 8.93% on Sep 15: What Investors Need To Know

• Arrowhead shares dropped despite positive Phase 1/2a data for ARO-DIMER-PA due to profit-taking. • The company reported annual revenue of $829.45M with a net loss of $1.63M. • Technical indicators show a MACD sell signal and an RSI of 27.985.

TradingKeyTue, Sep 15

Eli Lilly and Co's Score

0.07vs previous score
Forecast8.12
Financial Health7.41
Technical3.92
Valuation Dimensions8.05
Institutional Confidence10.00
Risk Assessment9.08

Media Coverage

Coverage Level

49°C

Very Low
Very High
Positive

Analyst Rating

Strong Buy
Buy
Hold
Sell
Strong Sell
BuyCurrent Rating
1306.807Target Price
+13.35%Upside Space
Current Rating2026-092026-082026-072026-062026-052026-042026-032026-02
Strong Buy101010111110109
Buy1717171616141515
Hold66778989
Sell11110000
Strong Sell00000000

Eli Lilly and Co Technical Analysis

1m
5m
15m
30m
1h
2h
4h
D
W
M
1m
5m
15m
D

Technical Indicators

Buy

Summary

Buy

Moving Average

Strong buy

Financial Indicators

Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.
Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
7.95/6.01
Revenue / Forecast
22.97B/20.73B

Eli Lilly and Co Profile

SectorPharmaceuticals
Ticker SymbolLLY
Number of employees47000
CountryUnited States of America

Ownership

ShareholdersProportion
Lilly Endowment, Inc.9.76%
Vanguard Capital Management, LLC5.67%
PNC Investments LLC5.43%
BlackRock Institutional Trust Company, N.A.4.44%
Shareholder TypesProportion
Investment Advisor46.65%
Investment Advisor/Hedge Fund19.18%
Foundation9.76%
Research Firm2.14%

FAQs

What is the current price of Eli Lilly and Co (LLY)?

The current price of Eli Lilly and Co (LLY) is 1152.93.

What is the symbol of Eli Lilly and Co?

The ticker symbol of Eli Lilly and Co is LLY.

What is the 52-week high of Eli Lilly and Co?

The 52-week high of Eli Lilly and Co is 1292.65.

What is the 52-week low of Eli Lilly and Co?

The 52-week low of Eli Lilly and Co is 707.59.

What is the market capitalization of Eli Lilly and Co?

The market capitalization of Eli Lilly and Co is 1.08T.

Is Eli Lilly and Co (LLY) currently rated as Buy, Hold, or Sell?

According to analysts, Eli Lilly and Co (LLY) has an overall rating of Buy, with a price target of 1306.81.

What is the Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY)?

The Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY) is 28.20.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.